Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Christoph Wanner"'
Autor:
Gurbey Ocak, Rianne Boenink, Marlies Noordzij, Willem Jan W. Bos, Bjorn E. Vikse, Aleix Cases, Julia Kerschbaum, Jaakko Helve, Maurizio Nordio, Mustafa Arici, Lucile Mercadal, Christoph Wanner, Runolfur Palsson, Kristine Hommel, Johan De Meester, Myrto Kostopoulou, Rafael Santamaria, Emilio Rodrigo, Helena Rydell, Samira Bell, Ziad A. Massy, Kitty J. Jager, Anneke Kramer
Publikováno v:
e227624
JAMA Network Open
Ocak, G, Boenink, R, Noordzij, M, Bos, W J W, Vikse, B E, Cases, A, Kerschbaum, J, Helve, J, Nordio, M, Arici, M, Mercadal, L, Wanner, C, Palsson, R, Hommel, K, De Meester, J, Kostopoulou, M, Santamaria, R, Rodrigo, E, Rydell, H, Bell, S, Massy, Z A, Jager, K J & Kramer, A 2022, ' Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis ', JAMA network open, vol. 5, no. 4, :e227624 . https://doi.org/10.1001/jamanetworkopen.2022.7624
Jama Network Open, 5(4). AMER MEDICAL ASSOC
JAMA network open. American Medical Association
JAMA Network Open
Ocak, G, Boenink, R, Noordzij, M, Bos, W J W, Vikse, B E, Cases, A, Kerschbaum, J, Helve, J, Nordio, M, Arici, M, Mercadal, L, Wanner, C, Palsson, R, Hommel, K, De Meester, J, Kostopoulou, M, Santamaria, R, Rodrigo, E, Rydell, H, Bell, S, Massy, Z A, Jager, K J & Kramer, A 2022, ' Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis ', JAMA network open, vol. 5, no. 4, :e227624 . https://doi.org/10.1001/jamanetworkopen.2022.7624
Jama Network Open, 5(4). AMER MEDICAL ASSOC
JAMA network open. American Medical Association
Importance: During the past decades, improvements in the prevention and management of myocardial infarction, stroke, and pulmonary embolism have led to a decline in cardiovascular mortality in the general population. However, it is unknown whether pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e6c618c9e12476946c434247a50db02
https://hdl.handle.net/11250/3011780
https://hdl.handle.net/11250/3011780
Autor:
Ajay K, Singh, Kevin, Carroll, Vlado, Perkovic, Scott, Solomon, Vivekanand, Jha, Kirsten L, Johansen, Renato D, Lopes, Iain C, Macdougall, Gregorio T, Obrador, Sushrut S, Waikar, Christoph, Wanner, David C, Wheeler, Andrzej, Więcek, Allison, Blackorby, Borut, Cizman, Alexander R, Cobitz, Rich, Davies, Jo, Dole, Lata, Kler, Amy M, Meadowcroft, Xinyi, Zhu, John J V, McMurray, Jorge, Posada
Publikováno v:
The New England journal of medicine. 385(25)
Background: \ud Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adv
Autor:
Nicholas C. Chesnaye, Fergus Caskey, Marie Evans, Juan Jesus Carrero, Claudia Torino, Friedo W. Dekker, Christoph Wanner, Catherine M. Clase, Maciej Szymczak, Edouard L Fu, Merel van Diepen, Hein Putter, Kitty J Jager
Publikováno v:
BRITISH MEDICAL JOURNAL, 375. BMJ PUBLISHING GROUP
BMJ (Clinical research ed.), 375:e066306. British Medical Association
Fu, E L, Evans, M, Carrero, J J, Putter, H, Clase, C M, Caskey, F J, Szymczak, M, Torino, C, Chesnaye, N C, Jager, K, Wanner, C, Dekker, F W & van Diepen, M 2021, ' Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease : nationwide cohort study ', BMJ . https://doi.org/10.1136/bmj-2021-066306
The BMJ
BMJ (Clinical research ed.), 375:e066306. British Medical Association
Fu, E L, Evans, M, Carrero, J J, Putter, H, Clase, C M, Caskey, F J, Szymczak, M, Torino, C, Chesnaye, N C, Jager, K, Wanner, C, Dekker, F W & van Diepen, M 2021, ' Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease : nationwide cohort study ', BMJ . https://doi.org/10.1136/bmj-2021-066306
The BMJ
ObjectiveTo identify the optimal estimated glomerular filtration rate (eGFR) at which to initiate dialysis in people with advanced chronic kidney disease.DesignNationwide observational cohort study.SettingNational Swedish Renal Registry of patients r
Autor:
Sanam Ebtehaj, Christopher C. Kaltenecker, Uwe J. F. Tietge, Bernd Genser, Vera Krane, Chantal Kopecky, Christiane Drechsler, Johannes J. Kovarik, Christoph Wanner, Mojtaba Parvizi, Marcus D. Säemann, Thomas Weichhart, Marlies Antlanger
Publikováno v:
Journal of the American Society of Nephrology, 28(3), 769-775. AMER SOC NEPHROLOGY
The cardioprotective effect of HDL is thought to be largely determined by its cholesterol efflux capacity, which was shown to inversely correlate with atherosclerotic cardiovascular disease in populations with normal kidney function. Patients with ES
Publikováno v:
Blood Purification. 41:247-253
Background: This study investigated in a North American patient population the longer-term treatment effects of the phosphate binder, colestilan, in patients with CKD Stage 5D and hyperphosphataemia. Methods: One hundred and sixteen CKD Stage 5D pati
Autor:
Rupert Bauersachs, Joachim Gerss, Sabine Jürgensmeyer, Günter Breithardt, Paulus Kirchhof, Christiane Engelbertz, Christoph Wanner, Holger Reinecke
IntroductionPatients with end-stage kidney disease requiring maintenance haemodialysis treatment experience a dramatic cardiovascular morbidity and mortality. Due to the high atherosclerotic and arteriosclerotic burden and profound alterations in hae
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f0feae1833686181d36ce887618e8d
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-225156
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-225156
Autor:
Christoph Wanner, Bruce E. Reidenberg, Dirk Stalleicken, Bruce Polsky, Antony Pfaffle, Alla Shelip, Mariana Castanheira
Catheter-related bloodstream infections (CRBSI) are major complications for patients with life-threatening conditions requiring chronic vascular catheterization. The wide range of etiologic microbes and the ongoing development of resistance to antimi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca4a5c6523edab8a071917bfdc0fe43
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/22509
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/22509
Autor:
Andreas Schneider, Eberhard Ritz, Hubert Scharnagl, Christoph Wanner, Götz Gelbrich, Stefan Pilz, Christiane Drechsler, Iain C. Macdougall, Lena Gutjahr-Lengsfeld
Publikováno v:
Nephron Clinical Practice. 128:147-152
Background: Dose requirements of erythropoietin-stimulating agents (ESAs) can vary considerably over time and may be associated with cardiovascular outcomes. We aimed to longitudinally assess ESA responsiveness over time and to investigate its associ
Autor:
Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan C. Craig, Dick de Zeeuw, Bo Feldt-Rasmussen, Bengt Fellström, Adeera Levin, David C. Wheeler, Rob Walker, William G. Herrington, Colin Baigent, Martin J. Landray, Charles Tomson, Christoph Wanner, Vera Krane, Jonathan Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Mike Gaziano, Bertram Kasiske, Ziad A. Massy, Udom Krairittichai, Vuddidhej Ophascharoensuk, Hallvard Holdaas, Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Carola Grönhagen-Riska, Tanaji Dasgupta, Will Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen, Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins
Publikováno v:
Journal of the American Society of Nephrology, 25(8), 1825-1833. AMER SOC NEPHROLOGY
Lowering LDL cholesterol reduces the risk of developing atherosclerotic events in CKD, but the effects of such treatment on progression of kidney disease remain uncertain. Here, 6245 participants with CKD (not on dialysis) were randomly assigned to s
Publikováno v:
Clinical Nephrology. 78:189-197
Background Continuous erythropoietin receptor activator (C.E.R.A.) is routinely given once every 2 weeks to correct hemoglobin (Hb) level, but monthly use is recommended in the maintenance phase. Patients and methods In an open-label, single- arm, mu